Back
Compare AU
Compare SSO vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the State Street SPDR S&P/ASX Small Ordinaries ETF (SSO) and the Betashares Global Healthcare Currency Hedged ETF (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
SSO | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 6 | 75 |
Median incremental investment | $1,000.00 | $742.79 |
Median investment frequency | Weekly | Monthly |
Median total investment | $1,516.22 | $1,802.00 |
Average age group | > 35 | > 35 |
Key Summary
SSO | DRUG | |
|---|---|---|
Strategy | SSO.AX was created on 2011-04-13 by State Street . The fund's investment portfolio concentrates primarily on small cap equity. The State Street SPDR S&P/ASX Small Ordinaries ETF seeks to closely track, before fees and expenses, the returns of the S&P/ASX Small Ordinaries Index. | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | Paladin Energy Ltd (1.81 %) Vault Minerals Ltd (1.57 %) Alcoa Corp Chess Depository Receipt (1.48 %) | BRL - BRAZILIAN REAL (0 %) AUD - AUSTRALIA DOLLAR (0 %) CHF - SWISS FRANC (0 %) |
Top 3 industries | Financials (38.86 %) Materials (33.04 %) Other (32.33 %) | Other (75.91 %) Communication Services (33.53 %) Health Care (23.80 %) |
Top 3 countries | Australia (88.50 %) United States (3.68 %) New Zealand (3.50 %) | United States (69.91 %) Switzerland (10.93 %) United Kingdom of Great Britain and Northern Ireland (7.38 %) |
Management fee | 0.5 % | 0.57 % |
Key Summary
SSO | DRUG | |
|---|---|---|
Issuer | State Street | BetaShares |
Tracking index | S&P ASX Small Ordinaries | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.5 % | 0.57 % |
Price | $16.13 | $8.45 |
Size | $28.132 million | $163.973 million |
10Y return | 38.45 % | N/A |
Annual distribution yield (5Y) | 5.74 % | 1.92 % |
Market | ASX | ASX |
First listed date | 13/04/2011 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
SSO | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 6 | 75 |
Median incremental investment | $1,000.00 | $742.79 |
Median investment frequency | Weekly | Monthly |
Median total investment | $1,516.22 | $1,802.00 |
Average age group | > 35 | > 35 |
Pros and Cons
SSO | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
SSO | DRUG |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |